Cardiovascular Research

Cardiovascular Research 2005 66(2):245-255; doi:10.1016/j.cardiores.2004.11.008

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Google Scholar Articles by Willems, L. Articles by Headrick, J. P. Search for Related Content PubMed PubMed Citation Articles by Willems, L. Articles by Headrick, J. P. Social Bookmarking          What's this?

Copyright © 2004, European Society of Cardiology

Adenosine-mediated cardioprotection in the aging myocardium

Laura Willems, Kevin J. Ashton and John P. Headrick^*

Heart Foundation Research Centre, School of Health Science, Griffith University, Southport, QLD 4217, Australia

^* Corresponding author. Tel.: +61 7 5552 8292; fax: +61 7 5552 8802. Email address: J.Headrick{at}griffith.edu.au

Received 28 September 2004; revised 21 October 2004; accepted 2 November 2004

	Abstract

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
With aging, it appears the heart's ability to withstand injury declines markedly. Unfortunately, the incidence of ischemic disorders increases dramatically with age. Though the genesis of the ischemia-intolerant phenotype is incompletely understood (and likely multi-factorial), it may involve changes in intrinsic cardioprotective responses. In this respect we and others have interrogated the role of the adenosine receptor (AR) system in dictating ischemic tolerance and the impact of age on AR-mediated cardioprotection. It is intriguing to note ARs impact on many processes implicated in myocardial ‘aging’: adenosine counters Ca²⁺ influx and oxidant injury, modifies substrate metabolism to improve tolerance, is pro-angiogenic, inhibits myocardial fibrosis, and can limit apoptosis. Thus, dysregulation of the AR system could contribute to many features of aged hearts (including ischemic intolerance). The latter is borne out by observations that AR-mediated protective responses decline with intrinsic tolerance and that transgenic manipulation of the AR system restores intrinsic tolerance and protective responses in aged hearts. Mechanisms underlying failure in adenosinergic protection remain undefined. Here we review data on the effects of aging on cardiovascular AR transcription and expression, generation of signal (adenosine formation), and protective signaling coupled to ARs.

KEYWORDS Adenosine; Adenosine receptors; Aging; Cardioprotection; Cellular Signalling; Ischemia

	1. Introduction

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
Despite a decline in mortality rates over the last decade, ischemic heart disease remains a leading cause of death and disability in developed countries, and is the single greatest cause of death in individuals over 65 years of age. Coronary artery disease affects 50% of those older than 65, contributing to an increased incidence of angina, myocardial infarction, arrhythmia, congestive heart failure, and sudden death. The age of hearts employed in cardiac transplant is also increasing in an attempt to expand the donor pool [1], and surgical ischemia-reperfusion in the older population is increasing with expanded use of thrombolysis, recanalization, and revascularization. Unfortunately, advanced age ( 70 years) is a significant risk factor for operative mortality during cardiac surgery in coronary artery bypass, and age is an adverse prognostic factor in morbidity and mortality following a myocardial infarction. Estimates in the USA indicate up to 80% of deaths from coronary artery disease occur in those over the age of 65 [2]. The problem is growing–it is anticipated the elderly population may nearly double (to 25%) within 25–30 years. Morbidity and mortality attributed to cardiovascular disease will thus increase dramatically. It is thus something of a paradox that most research into the pathophysiology and therapy of cardiovascular disease has been undertaken in young adult tissue/models. The initial exciting potential of such potent stimuli as preconditioning must now be tempered by emerging evidence of limited utility in the "at-risk" aged population [3–5]. Aged myocardium likely requires specific management strategies [4], not evident from studies in young tissue.

Aging-related ischemic intolerance has been documented in multiple species including humans [3–16]. Genesis of the intolerant phenotype is not understood, though is likely multi-factorial (a "single" molecular basis of intolerance seems improbable). Amongst other things, cytosolic Ca²⁺ handling may be impaired [7,9,17,18], energy and substrate metabolism altered [12], oxidant injury exaggerated [11,19,20], gene expression modified [11,17–20], membrane structure and function altered [21,22], mitochondrial function impaired [8,22–24], apoptosis potentially enhanced [25,26], capillary/arteriolar density reduced and myocardial fibrosis and hypertrophy enhanced [27]. These factors may all contribute to intolerance, and have attracted attention. One possibility, less extensively investigated, is that endogenous or intrinsic "cardioprotective" processes, such as the AR system, may be impaired.

	2. Age-related failure of intrinsic cardioprotection–the adenosine receptor system

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
The heart possesses a range of retaliatory mechanisms designed to provide resistance to injurious stimuli. Of these, considerable evidence points to an important role for the adenosine receptor (AR) system [28–32]. The ARs were attributed with regulatory functions in the heart and vessels three-quarters of a century ago [33]. More recent data indicate that adenosine is an endogenous determinant of myocardial ischemic tolerance [34–40]. Adenosine acts through 4 G-protein coupled receptor (GPCR) subtypes–the A₁, A_2A, A_2B and A₃ARs [30,32]–each encoded by a distinct adenosine receptor gene (Ador). Adenosine also enhances tolerance to ischemia via metabolic substrate effects [32,40,41]. Adenosinergic cardioprotection in ischemic-reperfused hearts involves reductions in oncotic [41–45] and apoptotic death [46], and improved functional outcomes [28–32,37,43]. Whether ARs specifically protect against reversible injury is difficult to ascertain, although AR agonism enhances post-ischemic contractility in models with minimal irreversible injury [37,43,47–49]. Recent work supports differential effects of acute adenosine [41,50] vs. transient adenosinergic preconditioning [51], consistent with multiple pathways of protection. In terms of cellular targets, adenosine appears to directly protect cardiomyocytes or myocardial tissue (likely via A₁ and A₃ARs) [32,49,52], and additionally protects via limiting inflammation and injurious interactions between inflammatory cells and vascular and myocardial tissue [30,32,34,38,42,53]. Though anti-inflammatory and "extra-cardiac" responses are important in adenosinergic protection [30,53], and as noted below may be altered with aging, further detailed description of these processes is unfortunately beyond the scope of the current review.

The different cardioprotective effects of AR agonism have been verified in animal [28–32,53] and human tissue [52,54,55]. However, few studies have addressed the possibility that altered AR-mediated protection might underlie specific cardiovascular disorders, though there is evidence to support this. Hypertrophic hearts, for example, display abnormal adenosinergic signaling [56,57], and dysregulated adenosine formation [58]. In the context of aging, we and others have acquired data demonstrating significant age-related changes in AR signaling [59–63], and more recently failure in AR-mediated protection against cell death and contractile dysfunction [16,64,65]. Interestingly, ARs impact on many processes implicated in cardiovascular "aging", regulating Ca²⁺ influx and oxidant injury [29,30,32,49], substrate metabolism [37], angiogenesis [67], myocardial fibrosis [68], and apoptotic processes [46]. Given evidence of a role for ARs in intrinsic cardioprotection [34–40], mediation of preconditioning [69,70], and modifying the above-mentioned processes, alterations in AR signalling could contribute both to ischemic intolerance and emergence of other features of aged myocardium. Data reveals failure in AR protection parallels the decline in intrinsic resistance to ischemia in aging mice (Fig. 1).

View larger version (31K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 1 Aging-related reduction in functional recovery from 20 min global ischemia in young (2 month), mature (8 month) and old (18 month) C57/Bl6 mouse hearts. Recovery of left ventricular pressure was assessed after 60 min reperfusion in untreated and adenosine treated hearts (n=6–9). Also shown is relative development of ischemic "intolerance" (% maximal decline in tolerance observed to 27 months of age –data modified from Refs. [15,103]).

 
Several studies support impaired adenosine responses in aged heart [59–62,64,71–73], though findings regarding AR expression/signaling vary [16,60,71]. Our recent data verifies failure in adenosinergic protection with even moderate aging in mouse [16], consistent with findings of Gao et al. [64] and Schulman et al. [65] in aged rat hearts. Age limits effects of ARs on both contractile outcome and oncotic death during ischemia-reperfusion [16,64,65], and reduces protection via both pre-ischemic AR agonism [65] and adenosine treatment throughout ischemia-reperfusion [16,64]. The molecular basis for the global failure in adenosinergic cardioprotection remains undefined. However, evidence points to failed activation of signaling distal to mitochondrial ATP-sensitive K⁺ (mito K_ATP) channels [16]. Failure in AR-mediated cardioprotection may occur at the level of ARs themselves (expression and coupling), generation of protective "signal" (adenosine formation), and/or at sites within signaling cascades triggered by ARs. Potential sites are depicted diagrammatically in Fig. 2.

View larger version (42K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 2 Schematic of adenosinergic cardioprotective signalling. Possible aging are highlighted in italicized text. Pathways of protection remain unclear, though evidence supports roles for PKC, mito KATP channels, ROS generation, and MAPKs. There is some support for PI3-kinase signaling. Abbreviations: AK, adenosine kinase; mito KATP, mitochondrial ATP-sensitive K+ channels; PKC, protein kinase C; PL, phospholipase; PLC, phospholipase C; PLD, phospholipase D; ROS, reactive oxygen species.

 

	3. Intrinsic cardioprotection via adenosine receptors: effects of aging

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
Endogenous adenosine may protect via one or all of the four characterized AR sub-types–A₁, A_2A, A_2B, and A₃ARs [28–32]. All are considered to be expressed within cardiovascular cells. Studies in different species verify endogenous adenosine contributes to intrinsic ischemic tolerance [34–40], and support cardioprotective roles for A₁ARs in vitro and in vivo [35,37,39], and for A₂ARs in vivo [34]. Anti-ischemic effects of A₁ARs appear direct (at cardiomyocytes), since similar protection is observed in isolated hearts, cardiomyocytes, and in vivo [28,32,35,37,49,52,54]. Protective A₂AR effects involve modulation of vascular function, platelet adhesion and neutrophil activation [34,35,42,53,74], and are absent in cardiomyocytes [75] and in vitro models lacking blood [37,45,76]. Nonetheless, cardiomyocyte Adora2a mRNA expression [77], and functional A_2AAR responses in cardiomyocytes [77–79] implicate a functional myocardial A_2AAR (of obscure function). There is currently no direct evidence for acute A_2BAR mediated cardioprotection, partially due to lack of selective A_2BAR agonists/antagonists.

In contrast to A₁ and A₂ARs, there is little evidence that intrinsically activated A₃ARs mediate protection–A₃AR antagonists have no effect on ischemic outcomes in myocytes [80] or hearts [81]. A₃AR overexpression enhances tolerance [82], implying an intrinsic function in cardioprotection. However, markedly elevated A₃AR expression will exaggerate sensitivity to endogenous adenosine and thus the role of the receptor in wild-types. As shown by Hill et al. [83], the A₃AR is over an order of magnitude less sensitive to adenosine than A₁ARs. Thus, A₁ARs will be intrinsically activated to a greater extent than A₃ARs during ischemia.

Given a demonstrable role of A₁AR and A₂ARs in determining ischemic tolerance, changes in expression/functionality could contribute to evolution of ischemic intolerance. In preliminary transcriptional analysis of moderately aged (16–18 month) mice under ischemic and normoxic conditions [84], we detect down-regulation of genes encoding heat-shock and stress-inducible proteins, contractile proteins, transcription factors and signal transducers. Similar age associated changes have been observed in cardiomyocytes [85]. Many genes identified have putative roles in ischemic tolerance, and in AR-mediated protection. Indeed, in a recent micro-array study, 15–20% of aging-related transcriptional changes were involved in GPCR signaling [73], and included changes in Adora1 mRNA.

In terms of A₁ARs, work in mouse hearts verifies no change in normoxic expression [16], in agreement with earlier findings of Cai et al. [60] for rat, and consistent with a lack of effect of aging on Adora1 mRNA levels in mice [16,87]. The latter study [87] also detected ischemic repression of Adora1 in aged (but not young) hearts. If translated into repressed A₁AR expression, this may contribute to poor outcome at later time points in aged vs. young tissue. Despite no change in baseline A₁AR expression in rat [60] and mouse [16], age-related changes in Adora1 mRNA are observed, though findings vary. Arosio et al. [88] and Dobson et al. [73] observed elevations in Adora1 whereas Jenner et al. [89] reported a 5-fold reduction in Adora1 with age. Irrespective of effects of age on mRNA, it appears that changes do not translate into altered A₁AR expression [16,60].

While there is little evidence for alterations in cardiac A₁AR density, the study of Cai et al. [60] revealed reduced coupling between A₁ARs and G-proteins, leading to reduced A₁AR responsiveness. Other work confirms the importance of changes in receptor–effector coupling, rather than A₁AR expression, in dictating cardiac AR sensitivity [90]. Consistent with impaired A₁AR activation of downstream effectors, we show A₁AR overexpression overcomes age-related failure in adenosinergic protection and restores ischemic tolerance to levels in young tissue [16].

Despite no direct studies of aging-related changes in A_2A or A_2BAR expression, it is interesting to focus on these sub-types for a moment, as there is unequivocal data indicating aging limits cardiovascular A₂AR sensitivity [59,63]. If such changes extend to A₂ARs implicated in reducing infarct size and post-ischemic inflammatory responses in vivo [34,35,53,74], this form of cardioprotection may also decline with age. There is indirect evidence age impairs A₂AR expression, since A_2AAR transcription is significantly reduced in rat myocardium [88,89]. On the other hand, A_2BAR transcription appears induced in rat [88] and mouse [87]. There are also no direct studies of effects of aging on cardiovascular expression of A₃ARs, though recent work indicates Adora3 mRNA is repressed with age in murine myocardium [87]. It would be of interest to examine effects of age on ischemic tolerance in models of cardiac A₃AR overexpression [82].

At a post-translational level, impaired GPCR responsiveness in senescent cells (of non-cardiac origin) has been attributed to up-regulation of caveolin expression [91], and manipulation of caveolin expression restores cellular responsiveness to GPCR stimuli [91,92]. Lasley et al. have observed translocation of A₁ARs from caveolae upon agonist stimulation [93], a form of compartmentalization that may explain lack of direct effects of A₁AR agonism under certain conditions. Given these latter findings [93], and effects of age on caveolins [91], it is possible that age-related reductions in AR-mediated protection against ischemic injury [16,64,65] may be related to altered caveolin expression and receptor interactions.

	4. Generation of the protective "trigger"–adenosine formation

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
Ischemic intolerance could result from impaired endogenous activation of ARs. During ischemia/hypoxia, [adenosine] increases by an order of magnitude or more [32,39,69,94,95], triggering AR responses including cardioprotection. Myocardial adenosine formation occurs primarily via intra- and extracellular dephosphorylation of 5'-AMP via 5'-nucleotidases [32]. Adenosine is derived from cardiomyocytes, endothelial cells, and fibroblasts. However, endothelial-derived adenosine accounts for only 15–25% of basal release [96,97], and even less during ischemia/hypoxia [98]. Though problematic to measure relevant interstitial concentrations, a variety of methods (including microdialysis) suggest these are sufficient to activate cardiovascular receptors [39,69,94,95,99]. This is validated by actions of AR antagonists [34–36,39,69].

Few studies have assessed effects of aging and senescence on interstitial adenosine levels and handling. Early work by Ramani et al. [100] provided preliminary support that reduced adenosine contributes to ischemic intolerance. However, they assessed total tissue adenosine, which substantially overestimates physiologically relevant "free" levels due to existence of tissue adenosine in bound forms (e.g. with s-adenosylhomocysteine; coupled to contractile proteins). Other studies verify age-related impairment of maintenance of adenine nucleotides in ischemic hearts [12], which enhances 5'-AMP and is predicted to increase adenosine accumulation. This is indeed what is observed in aged rat hearts during normoxia, ischemia, and adrenergic agonism [59,72]. Elevated extracellular adenosine in aged rat hearts does not appear to stem from altered 5'-nucleotidase or adenosine kinase activities [72]. However, since these activities were assessed in tissue homogenates it remains feasible that in vivo activities may differ as a result of alterations in the intracellular milieu. The enzymes are subject to control by Mg²⁺, H⁺ and inorganic phosphate (P_i), and data supports enhanced ischemic acidosis and P_i accumulation, and impaired recovery of P_i and Mg²⁺ in aged hearts [12]. Importantly, elevations in adenosine in aged rat hearts cannot explain profound reductions in ischaemic tolerance in this species. However, in contrast to rat tissues, recent work documents comparable normoxic adenosine in young and aged mouse hearts, and a decline in post-ischemic adenosine with aging [101]. Thus, changes in endogenous agonism may contribute to impaired ischemic tolerance in mice.

Changes in extracellular adenosine with age in some species hint at another potential explanation for ischemic intolerance with age. Bolling et al. [102] first presented the notion of adenosine protecting the heart as "substrate" (for nucleotide pool repletion) vs. "signal" (via AR activity). Manipulation of nucleotide repletion and adenosine handling enhances ischemic tolerance in mature hearts [40,41,48,102], and protection with adenosine is reduced by adenosine kinase inhibition, confirming a role for phosphorylation [41]. In preliminary studies we have shown that treatment with adenosine deaminase or kinase inhibitors fails to modify ischemic tolerance in aged hearts [103]. Thus, the "substrate" role of adenosine may be modified with aging. Recent work demonstrates specific shifts in purine catabolism in aged hearts, which may predispose to ischemic intolerance [101]. Accumulation of salvageable adenosine is reduced while accumulation of poorly salvaged hypoxanthine and xanthine is enhanced. These changes may limit myocardial capacity to replete adenine nucleotides post-ischemia.

	5. Cardioprotective signaling coupled to AR agonism

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
In addition to changes in AR expression, age may impair the signaling cascades coupled to ARs. It is interesting that other protective stimuli (e.g. ischemic preconditioning) may retain their ability to activate downstream protective proteins in aged myocardium, despite substantially impaired outcome [104]. Effects of A₁AR overexpression indicate that protective signaling can be harnessed in aged tissue if AR expression is sufficiently enhanced [16], verifying existence of exploitable protective processes. Before considering repression of AR-triggered signaling, it is worth noting that not all studies document repressed AR signaling with age, and that different signaling coupled to the same AR sub-type may be differentially altered. For example, while A₁AR-mediated cardioprotection is absent [16,64,65], A₁AR-mediated bradycardia and anti-adrenergic effects may be enhanced with aging [30,62,73]. Preservation (or amplification) of contractile or electrophysiological responses to A₁ARs, coupled with failure of A₁AR mediated cardioprotection [16,64,65], clearly demonstrates different signaling paths are selectively modulated during aging.

Numerous investigations document impaired function of GPCRs with age, and these generalized effects have been reviewed [91]. There is also evidence of impaired cardioprotection via other GPCRs [66]. A recent study by Dobson et al. [73] found that 15–20% of transcriptional changes in aged myocardium relate to GPCR signaling, lending weight to the notion of generally impaired GPCR signaling. With respect to AR-mediated cardioprotection, signaling appears to involve G-protein mediated activation of phospholipases, PKC, mitochondrial (and possibly sarcolemmal) K_ATP channels, and potentially MAPK and PI3-kinase pathways [29–32]. Our own prior data, demonstrating conservation of protective responses to direct mito K_ATP channel activation, indicate the lesion in adenosinergic protection lies proximal to these channels [16]. However, given the possibility that mito K_ATP channels may present both a signaling intermediate and potential end-effector, since there remain discrepancies in effects of PKC inhibition placing the kinase distal and proximal to mito K_ATP channels [41,44,51,105,106], and since there is evidence that aging may impair protection via mito K_ATP activation [65], it is worth considering effects of aging at all levels of signaling. It is also worth mentioning that "parallel" paths may contribute to AR-mediated protection [107,108], providing signaling redundancy. This, of course, raises the question of how aging abrogates AR-mediated protection [16,64,65], and favors a sufficiently distal lesion to impact on multiple convergent paths (e.g. MAPK, PKC, PI3-kinase), and/or a lesion in the initial steps in AR signaling (e.g. G-protein function and phospholipase activity).

5.1. Phospholipase activation
The A₁ and A₃ARs couple to pertussis-sensitive G_i and G_o family proteins. Liang et al. demonstrate (in chick myocytes) that A₁AR and A₃AR mediated protection involves G_i-dependent activation of PLC activity (a short-lived response) and RhoA-dependent activation of phospholipase D (PLD; a more long-lived response), respectively [109]. The A_2A and A_2BARs activate adenylyl cyclase via G_s protein, and A_2BARs also trigger PLC activity via G_q protein [110]. Though not specifically addressed in cardiomyocytes, there is evidence that aging and/or cellular senescence impair PLC and IP3 activation [111,112], together with PLD activation [112,113]. Impaired activity of PLC and particularly PLD may not only involve altered upstream activation but also reduced expression [112]. No study has directly addressed the relevance of reduced phospholipase signaling to changes in anti-ischemic actions of adenosine.

5.2. PKC activity
Activation of PKC is considered crucial in adenosinergic protection, and is often thought to occur upstream of mito K_ATP channels [114]. This is consistent with failure of PKC inhibition to modulate protection via mito K_ATP channel activation [44], and abrogation of PKC-mediated protection with a mito K_ATP channel blocker [115]. On the other hand, PKC inhibition has been shown to eliminate protection via mito K_ATP channel openers [41,51,105,106], placing PKC downstream. To reconcile such differences, PKC could act up- and downstream of mito K_ATP channels (e.g. modulating mito K_ATP function and subsequently being modified by mito K_ATP channel-dependent signaling, including ROS generation) (Fig. 2).

The impact of age on PKC signaling has received some attention. Tani et al. [116,117] observe impaired PKC activation/translocation and altered PKC- expression with age. Data of Przyklenk et al. [118] indicate protective PKC signaling paths differ substantially in aged vs. young tissues, with a requisite role of PKC- in young but not aged tissues. If PKC does play a central role in AR-mediated protection [29,31,32], and is a point of convergence in signaling, these changes in activation/ translocation could certainly contribute to failure in AR-mediated cardioprotection with age.

5.3. K_ATP channels
Stimulation of mito K_ATP channel opening is required, under most conditions studied, for expression of the anti-ischemic actions of AR. The A₁AR can activate both sarcolemmal [119] and mitochondrial ATP sensitive K⁺ channels [32,41,44,51], the A₃AR also activates mito K_ATP channels [120,121], and acute and preconditioning responses to AR agonism appear mito K_ATP channel mediated [41,44,49,51,120,121]. However, there remains support for a role for sarcolemmal K_ATP channels [122,123], despite the shift in focus to mitochondrial channels. Failure in K_ATP activation could certainly limit AR-mediated protection, however mixed data exist regarding ability of mito K_ATP channel activation to protect aged tissue. In mice a mito K_ATP activator retains its ability to protect against ischemic injury despite lack of AR-mediated protection [16]. This suggests failure distal to ARs yet proximal to mito K_ATP channels. In contrast, Schulman et al. [65] observed failure in both AR and diazoxide-mediated preconditioning in aged rat hearts, implying failure in signaling distal to the mito K_ATP channel. Differing observations could reflect different signaling with acute protection vs. preconditioning [41,51], and may be species-related. Complicating interpretation, there is evidence that effects of the commonly employed K_ATP opener diazoxide and inhibitor 5-hydroxydecanoic acid may be unrelated to mito K_ATP channel modulation [124,125]. If these agents indirectly target ROS generation and mitochondrial function, as suggested by Hanley and colleagues [124], or act via sarcolemmal K_ATP channels, as suggested by Suzuki et al. [125], then it may be these sites as opposed to mito K_ATP channels themselves, that are altered with aging. Indeed, strong evidence indicates protection attributed to mito K_ATP channels requires sarcolemmal K_ATP activity [122,125–127]. Direct reductions in sarcolemmal K_ATP channel expression and functionality do occur with aging (reviewed in Ref. [128]), and may thus lead to ischemic intolerance and failed AR cardioprotection, in agreement with intolerant phenotypes evident with reduced K_ATP channel expression [126,127].

5.4. MAPK Signaling
The mitogen-activated protein kinase (MAPK) family has been implicated in cardioprotective responses to adenosine [108,129]. Fredholm et al. show all ARs couple to MAPKs in non-cardiac cells [130], and preliminary studies support a role for p38 MAPK in A₁AR mediated cardioprotection [131]. As noted by Gabai and Sherman [132], MAPK signaling may favor either cell death or survival depending on the balance of differing elements and pathways. Thus, subtle changes in MAPK signals with age may have profound effects on cellular outcome from ischemia and on effects of protective stimuli. Aging substantially reduces MAPK (JNK and ERK) activity/levels in rat myocardium [133,134]. Findings in the few studies of aged human hearts are equivocal, with studies generally undertaken in diseased groups of only moderate age (e.g. Refs. [135–137]). Changes appear to involve impaired activity in the absence of changes in protein content, and may reflect impaired levels of upstream receptor activation and/or changes in caveolin function [91,92]. Studies of effects of aging on transcriptional responses to oxidative stress reveal impairment of early response genes dependent on MAPK signaling and stress-response genes (e.g. Gadd45, JunB) [86].

5.5. PI3-kinase
Agonism of ARs can activate myocardial PI3-kinase via transactivation of tyrosine kinase [138]. A key target of PI3-kinase is Akt, which promotes cell survival and is implicated in cardioprotection [139]. There is evidence of repressed PI3-kinase expression in aged cardiac tissue [140], as in other tissues [141]. Immunohistochemical data verifies a decline in PI3-kinase expression and activity [142]. Additionally, Akt is repressed in aged cardiac tissue [142]. Such observations suggest the PI3-kinase/Akt pathway may well be of limited activity in aged myocardium, contributing to impaired intrinsic tolerance and adenosinergic protection. It should be noted, however, that preliminary data do not support essential roles for PI3-kinase/Akt signaling in A₁AR mediated protection against cardiomyocyte death [46], or in adenosine mediated preconditioning [143]. Thus, the relevance of repressed PI3-kinase/Akt signaling to impaired AR-mediated protection remains to be defined.

5.6. Nitric oxide signaling
There is evidence supporting adenosinergic protection via modulation of nitric oxide (NO) bioavailability. Adenosine-mediated preconditioning may trigger changes in NO synthase (NOS) activity [144], and acute A₁AR-mediated cardiac responses appear to be at least partially NO-dependent [145]. In mice, age-related changes in NO bioavailability parallel changes in adenosine-mediated protection [64]. However, there is also evidence that NO generation and iNOS activity are enhanced in aged mouse hearts [146]. Data for rats are equivocal. Recent work reveals impaired mitochondrial NOS activity in aging myocardium [147], while Ishihata et al. [148] observed no differences in basal NO release, though stimulated release was markedly reduced. Zieman et al. [149] detected increases in eNOS activity in aged rat heart whereas Chou et al. [150] report decreased eNOS activity with age. Precise changes in NO bioavailability with age, and their role in ischemic intolerance, remain to be more clearly defined. Nonetheless, impaired mitochondrial NO generation [147] and parallel changes in NO generation and cardioprotection [64] give credence to the possibility that alterations in NO signaling may contribute to impaired cardioprotection.

5.7. Anti-oxidant defense
There is evidence that A₁AR agonism protects through improving anti-oxidant defense [31,32]. Adenosine receptor activation reduces mitochondrial radical formation [49] and oxidant injury [151,152], and increases cellular anti-oxidant capacity [153]. Moreover, cardioprotection via mito K_ATP channel-dependent pathways may involve inhibition of reactive oxygen species (ROS) generation [154]. Given the central role of oxidant damage in both reversible and irreversible injuries, these effects may contribute to the resistant phenotype observed with adenosine receptor activation. Aging is associated with increased oxidant generation and impaired anti-oxidant defences [11,155,156]. The documented elevations in radical generation and repression of endogenous anti-oxidant systems with age would be consistent with impairment of the beneficial effects of the AR system on radical generation [49] and anti-oxidant defences [153].

	6. Relevance of failed adenosinergic cardioprotection

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
As already noted, the substantial evidence for intrinsic protection via ARs, coupled with parallel reductions in AR-mediated cardioprotection and intrinsic ischemic tolerance (Fig. 2), supports the idea that changes in adenosinergic protection may contribute to the ischemia-intolerant aged phenotype. This is further supported by the observation that enhanced A₁AR expression renders aged myocardium comparable to young myocardium in terms of ischemic tolerance [16]. Changes in the AR system may additionally impact on post-ischemic events, with evidence that adenosine may regulate remodeling. Findings of Dubey et al. [68] indicate A_2BARs normally inhibit cardiac fibroblast growth, and this group proposes A_2BARs play a key role in regulating cardiac remodeling associated with fibroblast proliferation. This has yet to be more directly tested, although the normal role of A_2BARs in regulating collagen synthesis and fibroblast growth is supported by other recent studies [157]. Since aging is associated with repression of A_2BAR responses in vascular tissue [63], it is possible a decline in fibroblast A_2BAR responses could enhance mitogenic/ fibrotic activity in aged tissue. Aging does impact on remodeling in experimental models and is associated with more advanced basal myocardial fibrosis [158,159].

Finally, age-related reductions in AR-mediated cardioprotection may be highly relevant to modest outcomes in recent clinical trials of adenosinergic therapies. Several placebo-controlled clinical trials have been conducted, including Acute Myocardial Infarction Study of Adenosine Trial (AMISTAD) I and II, Attenuation by Adenosine of Cardiac Complications (ATTACC), and ADMIRE (AmP579 Delivery for Myocardial Infarction REduction). In AMISTAD, infarct size was reduced and LV systolic function improved by adenosine, primarily in patients with anterior MI localization [160]. Morbidity and mortality were unaffected. In ATTACC, LV systolic function was unaffected, and there was a trend towards improved survival in patients again with anterior MI localization [161]. In ADMIRE, final infarct size was unaffected by the A₁/A₂ agonist studied (AMP579), though again there was a trend towards greater myocardial salvage in patients with anterior MI [162]. The disparity between these modest effects and more profound protection in animal models [28–32,34,35,42–44,53] may relate to the age of the patients. In ADMIRE the age range was 31 to 85, with similarly broad ranges and advanced ages in AMISTAD and ATTACC. Based on animal data (Fig. 1), failure in adenosinergic protection may occur well prior to senescence (by middle age), explaining lack of efficacy of adenosine-based therapies in clinical trials.

	7. Conclusions

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
The adenosine receptor system and adenosine metabolism play important roles in determining cardiac outcome from ischemic insult. Despite advances in knowledge regarding the role of adenosine and ARs in protecting young tissues, it is now clear these responses are substantially impaired (or eliminated) with aging. These changes themselves may be important in the genesis of the ischemia-intolerant phenotype with aging. Origins of this dysfunction remain to be identified, but are likely to be multi-factorial (Fig. 2). Evidence does implicate failure in signaling as opposed to AR expression and adenosine handling itself. Clarification of changes in cardioprotective signaling may not only provide insight into the genesis of ischemic intolerance, but ultimately permit manipulation of myocardial tolerance and post-ischemic outcome in older subjects at greatest risk of ischemic events.

	Acknowledgment

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 
Dr. Headrick is the recipient of a Career Research Fellowship from the National Heart Foundation of Australia.

	Notes

 
Time for primary review 19 days

	References

Top Abstract 1. Introduction 2. Age-related failure of... 3. Intrinsic cardioprotection... 4. Generation of the... 5. Cardioprotective signaling... 6. Relevance of failed... 7. Conclusions Acknowledgment References

 

1. Hauptman P.J., Kartashov A.I., Couper G.S., Mudge G.H., Aranki S.F., Cohn L.H., et al. Changing patterns in donor and recipient risk: a 10-year evolution in one heart transplant center. J. Heart Lung Transplant. (1995) 14:654–658.[ISI][Medline]
2. Gurwitz J.H., Goldberg R.J., Gore J.M. Coronary thrombolysis for the elderly? JAMA (1991) 265:1720–1723.[CrossRef][ISI][Medline]
3. Abete P., Ferrara N., Cioppa A., Ferrara P., Bianco S., Calabrese C., et al. Preconditioning does not prevent postischemic dysfunction in aging heart. J. Am. Coll. Cardiol. (1996) 27:1777–1786.[Abstract]
4. Mariani J., Ou R.C., Bailey M., Rowland M., Nagley P., Rosenfeldt F., et al. Tolerance to ischemia and hypoxia is reduced in aged human myocardium. J. Thorac. Cardiovasc. Surg. (2000) 120:660–667.[Abstract/Free Full Text]
5. Rosenfeldt F.L., Pepe S., Linnane A., Nagley P., Rowland M., Ou R., et al. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium. Biogerontology (2002) 3:37–40.[CrossRef][ISI][Medline]
6. Pahor M., Di Gennaro M., Cocchi A., Bernabei R., Carosella L., Carbonin P. Age-related incidence of reperfusion- and reoxygenation-induced ventricular tachyarrhythmias in the isolated rat heart. Gerontology (1985) 31:15–26.[ISI][Medline]
7. Frolkis V.V., Frolkis R.A., Mkhitarian L.S., Fraifeld V.E. Age dependent effects of ischemia and reperfusion on cardiac function and Ca²⁺ transport in myocardium. Gerontology (1991) 37:233–239.[ISI][Medline]
8. Lesnefsky E.J., Hoppel C.L. Ischemia-reperfusion injury in the aged heart: role of mitochondria. Arch. Biochem. Biophys. (2003) 420:287–297.[CrossRef][ISI][Medline]
9. Ataka K., Chen D., Levitsky S., Jimenez E., Feinberg H. Effect of ageing on intracellular Ca²⁺, pH_i, and contractility during ischemia and reperfusion. Circulation (1992) 86:371–376.
10. Misare B.D., Krukenkamp I.B., Levitsky S. Age-dependent sensitivity to unprotected cardiac ischemia: the senescent myocardium. J. Thorac. Cardiovasc. Surg. (1992) 103:60–64.[Abstract]
11. Boucher F., Tanguy S., Toufektsian M.-C., Besse S., Tressallet N., Favier A., et al. Age-dependent changes in myocardial susceptibility to zero flow ischemia and reperfusion in isolated perfused rat hearts: relation to antioxidant status. Mech. Ageing Dev. (1998) 103:301–316.[CrossRef][ISI][Medline]
12. Headrick J.P. Aging impairs functional, metabolic and ionic recovery from ischemia-reperfusion and hypoxia-reoxygenation. J. Mol. Cell. Cardiol. (1998) 30:1415–1430.[CrossRef][ISI][Medline]
13. Abete P., Cioppa A., Calabrese C., Pascucci I., Cacciatore F., Napoli C., et al. Ischemic threshold and myocardial stunning in the aging heart. Exp. Gerontol. (1999) 34:875–884.[CrossRef][ISI][Medline]
14. Azhar G., Gao W., Liu L., Wei J.Y. Ischemia-reperfusion in the adult mouse heart influence of age. Exp. Gerontol. (1999) 34:699–714.[CrossRef][ISI][Medline]
15. Willems L, Zatta A, Holmgren K, Ashton KJ, Headrick JP. Age-related changes in ischemic tolerance in male and female mouse hearts. J. Mol. Cell. Cardiol. [in press].
16. Headrick J.P., Willems L., Ashton K.J., Holmgren K., Peart J., Matherne G.P. Ischaemic tolerance in aged mouse myocardium: the role of adenosine and effects of A1 adenosine receptor overexpression. J. Physiol. (2003) 549:823–833.[Abstract/Free Full Text]
17. Assayag P., Charlemagne D., Marty I., de Leiris J., Lompre A.M., Boucher F., et al. Effects of sustained low-flow ischemia on myocardial function and calcium-regulating proteins in adult and senescent rat hearts. Cardiovasc. Res. (1998) 38:169–180.[Abstract/Free Full Text]
18. Cain B.S., Meldrum D.R., Joo K.S., Wang J.-F., Meng X., Cleveland J.C. Jr., et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J. Am. Coll. Cardiol. (1998) 32:458–467.[Abstract/Free Full Text]
19. Helenius M., Hanninen M., Lehtinen S.K., Salminen A. Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NF-B transcription factor in mouse cardiac muscle. J. Mol. Cell. Cardiol. (1996) 28:487–498.[CrossRef][ISI][Medline]
20. Leeuwenburgh C., Wagner P., Holloszy J.O., Sohal R.S., Heinecke J.W. Caloric restriction attenuates dityrosine cross-linking of cardiac and skeletal muscle proteins in aging mice. Arch. Biochem. Biophys. (1997) 346:74–80.[CrossRef][ISI][Medline]
21. Liu S.J., Wyeth R.P., Melchert R.B., Kennedy R.H. Aging-associated changes in whole cell K⁺ and L-type Ca²⁺ currents in rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. (2000) 279:H889–H900.[Abstract/Free Full Text]
22. Pepe S. Mitochondrial function in ischaemia and reperfusion of the ageing heart. Clin. Exp. Pharmacol. Physiol. (2000) 27:745–750.[CrossRef][ISI][Medline]
23. Lesnefsky E.J., Moghaddas S., Tandler B., Kerner J., Hoppel C.L. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J. Mol. Cell. Cardiol. (2001) 33:1065–1089.[CrossRef][ISI][Medline]
24. Wanagat J., Wolff M.R., Aiken J.M. Age-associated changes in function, structure and mitochondrial genetic and enzymatic abnormalities in the Fischer 344x brown Norway F1 hybrid rat heart. J. Mol. Cell. Cardiol. (2002) 34:17–28.[CrossRef][ISI][Medline]
25. Liu L., Azhar G., Gao W., Zhang X., Wei J.Y. Bcl-2 and Bax expression in adult rat hearts after coronary occlusion: age-associated differences. Am. J. Physiol. (1998) 275:R315–R322.[ISI][Medline]
26. Pollack M., Phaneuf S., Dirks A., Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann. N.Y. Acad. Sci. (2002) 959:93–107.[Abstract/Free Full Text]
27. Folkow B., Svanborg A. Physiology of cardiovascular aging. Physiol. Rev. (1993) 73:725–764.[Free Full Text]
28. Ely S.W., Berne R.M. Protective effects of adenosine in myocardial ischemia. Circulation (1992) 85:893–904.[Abstract/Free Full Text]
29. Sommerschild H.T., Kirkeboen K.A. Adenosine and cardioprotection during ischaemia and reperfusion. An overview. Acta Anaesthesiol. Scand. (2000) 44:1038–1055.[CrossRef][ISI][Medline]
30. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. (2001) 41:775–787.[CrossRef][ISI][Medline]
31. Mubagwa K., Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc. Res. (2001) 52:25–39.[Abstract/Free Full Text]
32. Headrick J.P., Hack B., Ashton K.J. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am. J. Physiol. Heart Circ. Physiol. (2003) 285:H1797–H1818.[Abstract/Free Full Text]
33. Drury A.N., Szent-Györgi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. (1929) 68:213–237.[Free Full Text]
34. Zhao Z.Q., McGee S., Nakanishi K., Toombs W.E., Johnston C.F., Ashar M.S., et al. Receptor-mediated cardioprotective effects of endogenous adenosine are exerted primarily during reperfusion after coronary occlusion in the rabbit. Circulation (1993) 88:709–719.[Abstract/Free Full Text]
35. Zhao Z.Q., Nakanishi K., McGee D.S., Tan P., Vinten-Johansen J. A₁ receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc. Res. (1994) 28:270–279.[Abstract/Free Full Text]
36. Rynning S.E., Brunvand H., Birkeland S., Hexeberg E., Grong K. Endogenous adenosine attenuates myocardial stunning by antiadrenergic effects exerted during ischemia and not during reperfusion. J. Cardiovasc. Pharmacol. (1995) 25:432–439.[ISI][Medline]
37. Finegan B.A., Lopaschuk G.D., Gandhi M., Clanachan A.S. Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A₁ receptor stimulation during reperfusion following ischaemia. Br. J. Pharmacol. (1996) 118:355–363.[ISI][Medline]
38. Seligmann C., Kupatt C., Becker B.F., Zahler S., Beblo S. Adenosine endogenously released during early reperfusion mitigates postischemic myocardial dysfunction by inhibiting platelet adhesion. J. Cardiovasc. Pharmacol. (1998) 32:156–163.[CrossRef][ISI][Medline]
39. Peart J., Headrick J.P. Intrinsic activation of A₁ adenosine receptors during ischemia and reperfusion improves ischemic tolerance. Am. J. Physiol. Heart Circ. Physiol. (2000) 279:H2166–H2175.[Abstract/Free Full Text]
40. Peart J., Matherne G.P., Cerniway R.J., Headrick J.P. Cardioprotection with adenosine metabolism inhibitors in ischemic-reperfused mouse heart. Cardiovasc. Res. (2001) 52:120–129.[Abstract/Free Full Text]
41. Peart J., Willems L., Headrick J.P. Receptor and non-receptor dependent mechanisms of cardioprotection with adenosine. Am. J. Physiol. Heart Circ. Physiol. (2003) 284:H519–H527.[Abstract/Free Full Text]
42. Todd J., Zhao Z.Q., Williams M.W., Sato H., Van Wylen D.G., Vinten-Johansen J. Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence. Ann. Thorac. Surg. (1996) 62:1364–1372.[Abstract/Free Full Text]
43. Auchampach J.A., Rizvi A., Qiu Y., Tang X.L., Maldonado C., Teschner S., et al. Selective activation of A₃ adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ. Res. (1997) 80:800–809.[Abstract/Free Full Text]
44. Miura T., Liu Y., Kita H., Ogawa T., Shimamoto K. Roles of mitochondrial ATP-sensitive K⁺ channels and PKC in anti-infarct tolerance afforded by adenosine A₁ receptor activation. J. Am. Coll. Cardiol. (2000) 35(l):238–245.[Abstract/Free Full Text]
45. Peart J., Flood A., Linden J., Matherne G.P., Headrick J.P. Adenosine mediated cardioprotection in ischemic reperfused mouse heart. J. Cardiovasc. Pharmacol. (2002) 39:117–229.[CrossRef][ISI][Medline]
46. Regan S.E., Broad M., Byford A.M., Lankford A.R., Cerniway R.J., Mayo M.W., et al. A₁ adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity. Am. J. Physiol. Heart Circ. Physiol. (2003) 284:H859–H866.[Abstract/Free Full Text]
47. Lasley R.D., Mentzer R.M. Jr. Protective effects of adenosine in the reversibly injured heart. Ann. Thorac. Surg. (1995) 60:843–846.[Abstract/Free Full Text]
48. McClanahan T.B., Ignasiak D.P., Martin B.J., Mertz T.E., Gallagher K.P. Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs. Basic Res. Cardiol. (1995) 90:176–183.[CrossRef][ISI][Medline]
49. Narayan P., Mentzer R.M. Jr., Lasley R.D. Adenosine A₁ receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes. J. Mol. Cell. Cardiol. (2001) 33:121–129.[CrossRef][ISI][Medline]
50. Flood A., Willems L., Headrick J.P. Cardioprotection with pre- and post-ischemic adenosine and A₃ receptor activation: differing mechanisms and effects on necrosis versus stunning. Drug Dev. Res. (2003) 58:447–453.[CrossRef][ISI]
51. Peart J., Headrick J.P. Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects. Cardiovasc. Res. (2003) 58:589–601.[Abstract/Free Full Text]
52. Carr C.S., Hill R.J., Masamune H., Kennedy S.P., Knight D.R., Tracey W.R., et al. Evidence for a role for both the adenosine A₁ and A₃ receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc. Res. (1997) 36:52–59.[Abstract/Free Full Text]
53. Vinten-Johansen J., Thourani V.H., Ronson R.S., Jordan J.E., Zhao Z.Q., Nakamura M., et al. Broad-spectrum cardioprotection with adenosine. Ann. Thorac. Surg. (1999) 68:1942–1948.[Abstract/Free Full Text]
54. Roscoe A.K., Christensen J.D., Lynch C. III. Isoflurane, but not halothane, induces protection of human myocardium via adenosine A₁ receptors and adenosine triphosphate-sensitive potassium channels. Anesthesiology (2000) 92:1692–1701.[CrossRef][ISI][Medline]
55. Wei M., Kuukasjarvi P., Laurikka J., Honkonen E.-L., Kaukinen S., Laine S., et al. Cardioprotective effect of adenosine pretreatment in coronary artery bypass grafting. Chest (2001) 120:860–865.[CrossRef][ISI][Medline]
56. Tang X.L., Wang H.X., Cho C.H., Wong T.M. Reduced responsiveness of [Ca²⁺]_i to adenosine A₁- and A₂-receptor stimulation in the isoproterenol-stimulated ventricular myocytes of spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1998) 31:493–498.[CrossRef][ISI][Medline]
57. Zhao X.H., Sun X.Y., Erlinge D., Edvinsson L., Hedner T. Downregulation of adenosine and P2X receptor-mediated cardiovascular responses in heart failure rats. Blood Press. (2000) 9:152–161.[CrossRef][ISI][Medline]
58. De Tata V., Gini S., Simonetti I., Fierabracci V., Gori Z., Ipata P.L., et al. The regional distribution of adenosine-regulating enzymes in the left and right ventricle walls of control and hypertrophic heart. Basic Res. Cardiol. (1989) 84:597–605.[CrossRef][ISI][Medline]
59. Headrick J.P. Impact of aging on adenosine levels, A₁/A₂ responses, arrhythmogenesis, and energy metabolism in rat heart. Am. J. Physiol. (1996) 270:H897–H906.[Medline]
60. Cai G., Wang H.Y., Gao E., Horwitz J., Snyder D.L., Pelleg A., et al. Reduced adenosine A₁ receptor and G alpha protein coupling in rat ventricular myocardium during aging. Circ. Res. (1997) 81:1065–1071.[ISI][Medline]
61. Fenton R.A., Lorbar M., Dobson J.G. Jr. Cardiovascular Biology of Purines. Burnstock G., Dobson J.G. Jr., Liang B.T., Linden J., eds. (1998) New York: Kluwer. 142–158.
62. Hinschen A.K., Rose'Meyer R.B., Headrick J.P. Age-related changes in A₁ adenosine receptor mediated bradycardia. Am. J. Physiol. Heart Circ. Physiol. (2000) 278:H789–H795.[Abstract/Free Full Text]
63. Hinschen A.K., Rose'Meyer R.B., Headrick J.P. Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J. Cardiovasc. Pharmacol. (2003) 41:73–80.[CrossRef][ISI][Medline]
64. Gao F., Christopher T.A., Lopez B.L., Friedman E., Cai G., Ma X.L. Mechanism of decreased adenosine protection in reperfusion injury of aging rats. Am. J. Physiol. Heart Circ. Physiol. (2000) 279:H329–H338.[Abstract/Free Full Text]
65. Schulman D., Latchman D.S., Yellon D.M. Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. (2001) 281:H1630–H1636.[Abstract/Free Full Text]
66. Peart J.N., Gross E.R., Gross G.J. Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction. J. Cardiovasc. Pharmacol. (2004) 43:410–415.[CrossRef][ISI][Medline]
67. Granger H.J., Meininger C., Ziche M., Hood J. Cardiovascular Biology of Purines. Burnstock, Dobson, Liang, Linden, eds. (1998) New York: Kluwer. 49–63.
68. Dubey R.K., Gillespie D.G., Jackson E.K. Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A_2B receptors. Hypertension (1998) 31:943–948.[Abstract/Free Full Text]
69. Headrick J.P. Ischemic preconditioning: bioenergetic and metabolic changes, and the role of endogenous adenosine. J. Mol. Cell. Cardiol. (1996) 28:1227–1240.[CrossRef][ISI][Medline]
70. de Jong J.W., de Jonge R., Keijzer E., Bradamante S. The role of adenosine in preconditioning. Pharmacol. Ther. (2000) 87:141–149.[CrossRef][ISI][Medline]
71. Gao E., Snyder D.L., Johnson M.D., Friedman E., Roberts J., Horwitz J. The effect of age on adenosine A₁ receptor function in the rat heart. J. Mol. Cell. Cardiol. (1997) 29:593–602.[CrossRef][ISI][Medline]
72. Lorbar M., Fenton R.A., Duffy A.J., Graybill C.A., Dobson J.G. Jr. Effect of aging on myocardial adenosine production, adenosine uptake and adenosine kinase activity in rats. J. Mol. Cell. Cardiol. (1999) 31:401–412.[CrossRef][ISI][Medline]
73. Dobson J.G. Jr., Fray J., Leonard J.L., Pratt R.E. Molecular mechanisms of reduced beta adrenergic signaling in the aged heart as revealed by genomic profiling. Physiol. Genomics (2003) 15:142–147.[Abstract/Free Full Text]
74. Zhao Z.Q., Todd J.C., Sato H., Ma X.L., Vinten-Johansen J. Adenosine inhibition of neutrophil damage during reperfusion does not involve K_ATP-channel activation. Am. J. Physiol. Heart Circ. Physiol. (1997) 273:H1677–H1687.[Abstract/Free Full Text]